학술논문
Sequential autologous and allogeneic stem cell transplantation for treatment of primary plasma cell leukemia: A case report
Document Type
Academic Journal
Author
Source
Molecular and Clinical Oncology. September 2023, Vol. 19 Issue 3
Subject
Language
English
ISSN
2049-9450
Abstract
Introduction Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell disorder (1,2). The prognosis of pPCL is poor. The median overall survival ~12 months based on patients [...]
Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma cell disorder, which accounts for ~70% of all PCL. Survival of pPCL remains poor, and is related with early mortality. There is no standard therapy for patients with pPCL. In the present study, a 26-year-old man who was diagnosed with pPCL was reported. The patient achieved stringent complete remission to the successful treatment of intensive chemotherapy combined with sequential autologous and allogeneic stem cell transplantation (SCT) followed by maintenance therapy with oral administration of ixazomib, thalidomide and dexamethasone (IRD regimen). Development of complex treatment algorithms that combine novel agents, SCT and post-transplantation remission strategies may translate into survival in patients with pPCL. Key words: plasma cell leukemia, stem cell transplantation, maintenance therapy, VTD-PACE regimen, IRD regimen
Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma cell disorder, which accounts for ~70% of all PCL. Survival of pPCL remains poor, and is related with early mortality. There is no standard therapy for patients with pPCL. In the present study, a 26-year-old man who was diagnosed with pPCL was reported. The patient achieved stringent complete remission to the successful treatment of intensive chemotherapy combined with sequential autologous and allogeneic stem cell transplantation (SCT) followed by maintenance therapy with oral administration of ixazomib, thalidomide and dexamethasone (IRD regimen). Development of complex treatment algorithms that combine novel agents, SCT and post-transplantation remission strategies may translate into survival in patients with pPCL. Key words: plasma cell leukemia, stem cell transplantation, maintenance therapy, VTD-PACE regimen, IRD regimen